Supplemental Data

A polymorphism of *HMGA1* is associated with increased risk of metabolic syndrome and related components

Eusebio Chiefari, Sinan Tanyolaç, Stefania Iiritano, Angela Sciacqua, Carmelo Capula, Biagio Arcidiacono, Aurora Nocera, Katiuscia Possidente, Francesco Baudi, Valeria Ventura, Giuseppe Brunetti, Francesco S. Brunetti, Raffaella Vero, Raffaele Maio, Manfredi Greco, Maria Pavia, Ugur Hodoglugil, Vincent Durlach, Clive R. Pullinger, Ira D. Goldfine, Francesco Perticone, Daniela Foti & Antonio Brunetti.

Contents:

Supplementary Table S1. General Characteristics of the Two Study Populations With or Without MetS

Italian population	**Units**	**MetS**	**Control**	***P***
Number of subjects	n	3405	5016	
Female/Male	n	1,767/1,638	2581/2,435	
Increased waist circumference				
Female (>88 cm)	n (%)	1,165 (65.9)	455 (17.6)	< 0.001
Male (>102 cm)	n (%)	897 (54.8)	262 (10.8)	< 0.001
BP ≥130/85 mmHg or therapy				
Female	n (%)	1,522 (86.1)	361 (14.0)	< 0.001
Male	n (%)	1,392 (85.0)	435 (17.9)	< 0.001
Low HDL-C or therapy				
Female (<50 mg/dL)	n (%)	1,335 (75.6)	235 (9.1)	< 0.001
Male (<40 mg/dL)	n (%)	1,082 (66.1)	129 (5.3)	< 0.001
Triglyceridemia ≥150 mg/dl or therapy				
Female	n (%)	902 (51.0)	91 (3.5)	< 0.001
Male	n (%)	1,041 (63.6)	107 (4.4)	< 0.001
FPG ≥110 mg/dL				
Female	n (%)	1,591 (90.0)	799 (31.0)	< 0.001
Male	n (%)	1,465 (89.4)	840 (34.5)	< 0.001
MetS components (NCEP ATP III)				
No component	n (%)	–	2569 (51.2)*	–
One component	n (%)	–	1179 (23.5)*	–
Two components	n (%)	_	1268 (25.3)*	–
Three components	n (%)	1,817 (53.4)*	–	–
Four components	n (%)	998 (29.3)*	–	–
Five components	n (%)	590 (17.3)*	–	–
Turkish population	**Units**	**MetS**	**Control**	***P***
Number of subjects	n	659	760	
Female/Male	n	476/183	424/336	
Increased waist circumference				
Female (>88 cm)	n (%)	269 (56.5)	153 (36.1)	< 0.001
Male (>102 cm)	n (%)	171 (93.4)	46 (13.7)	< 0.001
BP ≥130/85 mmHg or therapy				
Female	n (%)	235 (49.4)	108 (25.5)	< 0.001
Male	n (%)	171 (93.4)	83 (24.7)	< 0.001
Low HDL-C or therapy				
Female (<50 mg/dL)	n (%)	287 (60.3)	223 (52.6)	ns
Male (<40 mg/dL)	n (%)	174 (95.1)	135 (40.2)	< 0.001

Triglyceridemia ≥150 mg/dL or therapy				
Female	n (%)	179 (37.6)	5 (1.2)	< 0.001
Male	n (%)	172 (94.0)	2 (0.6)	< 0.001
FPG ≥110 mg/dL				
Female	n (%)	119 (25.0)	0 (0.0)	< 0.001
Male	n (%)	150 (82.0)	0 (0.0)	< 0.001
MetS components (NCEP ATP III)				
No component	n (%)	0	205 (27.0)*	
One component	n (%)	0	350 (46.0)*	
Two components	n (%)	0	205 (27.0)*	
Three components	n (%)	388 (58.9)*	0	
Four components	n (%)	190 (28.8)*	0	
Five components	n (%)	81 (12.3)*	0	

Fisher exact test has been used for comparisons of proportions;
NCEP ATP III, National Cholesterol Education Program Adult Treatment Panel III;
BP, blood pressure; HDL-C, high-density lipoprotein-cholesterol; FPG, fasting plasma glucose;
Values in parentheses are in percent with respect to total females or males, or with respect to total populations*.

Supplementary Table S2. Oligonucleotide sequences of both primers and probes used.

PCR and sequencing primers	Forward	5'-TTCTGAGGGGGTGGAAACAG-3'
	Reverse	5'-AGGGGTAGTCCCATCTCAAGT-3'
TaqMan detection primers	Forward	5'-GGGTGGAAACAGGTGATGACT-3'
	Reverse	5'-CGCTGGGCTCCTTCTGTAAA-3'
TaqMan MGB probes	Wild-type	5'-TGACTACCCCCTCTGTC-3'
	C-Ins	5'-TGACTACCCCCCTCTGTC-3'